NasdaqCM:CORTPharmaceuticals
Corcept Therapeutics (CORT) Is Up 21.5% After First-in-Class Lifyorli Cancer Approval - Has The Bull Case Changed?
Earlier this year, Corcept Therapeutics announced that the FDA approved Lifyorli (relacorilant) plus nab-paclitaxel for adults with previously treated platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, based on the ROSELLA trial’s dual primary endpoint success in progression-free and overall survival.
This approval introduces the first selective glucocorticoid receptor antagonist in oncology care, highlighting cortisol signaling as a new treatment pathway in...